Arca
Skip to content
Tools
Tools

Cell membrane

Subcellular in Homo sapiens that 6 drugs act on.

  • Drugs that act on it: 6
  • Approved: 2
  • In phases 1 to 3: 4
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Antibody-drug conjugate 1
  • Protein or peptide 2

Approved2

  • Deoxycholic acid
  • Nonoxynol 9

Phase 31

  • Belzupacap sarotalocan

Phase 23

  • Cetuximab sarotalocan
  • Idroxioleic acid
  • Onvitrelin ucalontide

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Esperance Pharmaceuticals Inc117%
    • Laminar Pharmaceuticals117%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Cell membrane disrupting agent.
    Deoxycholic acidApprovedAbbVieSmall moleculeDisrupting agent34
    Nonoxynol 9ApprovedJohnson & JohnsonSmall moleculeDisrupting agent1
    Belzupacap sarotalocanPhase 3Aura BiosciencesProtein or peptideDisrupting agent3
    Cetuximab sarotalocanPhase 2Rakuten MedicalAntibody-drug conjugateDisrupting agent2
    Idroxioleic acidPhase 2Laminar PharmaceuticalsSmall moleculeDisrupting agent0
    Onvitrelin ucalontidePhase 2Esperance Pharmaceuticals IncProtein or peptideDisrupting agent0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.
    Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With SepsisDeoxycholic acidPhase 2 / Phase 3Not yet recruitingTanta UniversityOct 1, 2026
    Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsDeoxycholic acid—RecruitingHaikou Affiliated Hospital of Central South University Xiangya School of MedicineAug 13, 2026
    AI-Augmented Diagnostic Assessment With ENLIGHT Versus Independent Pathologist ReviewNonoxynol 9Not applicableEnrolling by invitationHarvard Medical School (HMS and HSDM)Aug 3, 2026
    Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic ChildrenDeoxycholic acid—RecruitingHaikou Affiliated Hospital of Central South University Xiangya School of MedicineJul 24, 2026
    Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerDeoxycholic acidPhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJul 21, 2026
    EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic CancerCetuximab sarotalocanPhase 1 / Phase 2Not yet recruitingBrown UniversityJul 13, 2026
    Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal TumorsDeoxycholic acidPhase 2RecruitingJinling Hospital, ChinaJun 29, 2026
    Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.Deoxycholic acidNot applicableNot yet recruitingInstitute of Liver and Biliary Sciences, IndiaJun 23, 2026
    Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral HepatitisDeoxycholic acidNot applicableNot yet recruitingCombined Military Hospital, PakistanApr 13, 2026
    Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic HepatitisDeoxycholic acidPhase 2RecruitingUniversity Hospital, MontpellierJan 30, 2026
    A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesCetuximab sarotalocanPhase 3RecruitingRakuten Medical, Inc.Nov 21, 2024
    Suprachoroidal Administration in Subjects With Metastases to the ChoroidBelzupacap sarotalocanPhase 2RecruitingAura BiosciencesOct 16, 2024
    A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaBelzupacap sarotalocanPhase 3Active, not recruitingAura BiosciencesAug 23, 2023
    A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerBelzupacap sarotalocanPhase 1Active, not recruitingAura BiosciencesAug 2, 2022

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390826, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.